Elliott L. Fineman
Chief Executive Officer at Planet Biotechnology, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jim W. Larrick | M | - |
Planet Biotechnology, Inc.
 Planet Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Planet Biotechnology, Inc. identifies and develops promising antibodies and receptor-antibody fusion molecules for the treatment and prevention of infectious diseases including emerging diseases and bio-threat agents. The company was is headquartered in Hayward, CA. | - |
| Jeffrey S. Price | M | - |
Planet Biotechnology, Inc.
Planet Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Planet Biotechnology, Inc. identifies and develops promising antibodies and receptor-antibody fusion molecules for the treatment and prevention of infectious diseases including emerging diseases and bio-threat agents. The company was is headquartered in Hayward, CA. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Joseph Rubinfeld | M | 91 |
SuperGen, Inc.
 SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 14 years |
| Joi Ninomoto | M | - |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 1 years |
| Lance Kirk Hunsinger | M | - |
University of Baltimore
| 8 years |
| Susanna Chau | F | - |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | - |
| Marvin L. Laughlin | M | - |
Georgetown University
| 6 years |
| Ronald Spair | M | 58 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 2 years |
| James Manuso | M | 75 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 10 years |
| Harren Jhoti | M | 61 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | - |
| Joe Abraham | M | - |
Georgetown University
| 5 years |
| Gavin Choy | M | - |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | - |
| Donn Weinberg | M | - |
University of Baltimore
| 17 years |
| Michael Molkentin | M | 69 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 8 years |
| Harry Kopelman | M | - |
Georgetown University
| 4 years |
| O. James Lighthizer | M | - |
Georgetown University
| 3 years |
| Gary Edward Stroik | M | 70 |
Georgetown University
| 4 years |
| Lawrence Horn | M | - |
Georgetown University
| 1 years |
| Timothy O'Neill | M | - |
Georgetown University
| 2 years |
| Harvey Pitt | M | 79 |
Georgetown University
| 9 years |
| Robert P. Macina | M | - |
Georgetown University
| 4 years |
| Philip Winder | M | - |
Georgetown University
| 1 years |
| Richard J. Melnick | M | - |
Georgetown University
| 3 years |
| Bob Shanks | M | 71 |
Georgetown University
| 4 years |
| Thomas L. Mifflin | M | - |
Georgetown University
| 1 years |
| Ronald Kravit | M | - |
Georgetown University
| 4 years |
| Samuel W.T. Chu | M | 70 |
Georgetown University
| 4 years |
| Steven Kaplan | M | - |
Georgetown University
| 3 years |
| Edward W. Bernton | M | - |
Georgetown University
| 3 years |
| Stanard T. Klinefelter | M | - |
Georgetown University
| 3 years |
| Michael C. Jones | M | 74 |
Georgetown University
| 3 years |
| Fred Chapey | M | - |
Georgetown University
| 4 years |
| Barry Nathan Paster | M | 75 |
Georgetown University
| 3 years |
| Marcotte Bob | M | - |
Georgetown University
| 4 years |
| Gerard Johnson | M | - |
Georgetown University
| 4 years |
| Richard Eberle | M | - |
Georgetown University
| 4 years |
| Teresa Koncick | F | - |
Georgetown University
| 4 years |
| Samuel Lewis Navarro | M | 67 |
Georgetown University
| 4 years |
| M. Paul Martin | M | 65 |
Georgetown University
| 4 years |
| John Donnelly | M | - |
Georgetown University
| 2 years |
| Kuan Chi Sun | M | 75 |
Georgetown University
| 3 years |
| Jaleen Moroney | F | - |
Georgetown University
| 4 years |
| Howard Seife | M | - |
Georgetown University
| 3 years |
| Andrew Oleksiw | M | - |
Georgetown University
| 4 years |
| James K. Nash | M | - |
Georgetown University
| 4 years |
| Bart Waldman | M | - |
Georgetown University
| 3 years |
| Kenneth S. Slaughter | M | - |
Georgetown University
| 2 years |
| Maurice L. Offit | M | - |
Georgetown University
| 3 years |
| George Stapleton | M | - |
Georgetown University
| 4 years |
| Manuel Iglesias | M | 69 |
Georgetown University
| 4 years |
| Michael L. Blau | M | - |
Georgetown University
| 3 years |
| John F. Hartigan | M | - |
Georgetown University
| 3 years |
| Mildred Callear | F | - |
Georgetown University
| 3 years |
| Daphne J. Firth | F | - |
Georgetown University
| 4 years |
| John C. Wallendjack | M | - |
Georgetown University
| 3 years |
| Susan Balloch | F | - |
Georgetown University
| 4 years |
| Pierce B. Dunn | M | 72 |
Georgetown University
| 2 years |
| John Ritota | M | 73 |
Georgetown University
| 3 years |
| Jerome Powell | M | - |
Georgetown University
| 4 years |
| Robert Jacoboski | M | 67 |
Georgetown University
| 4 years |
| Bruce F. Taub | M | - |
Georgetown University
| 2 years |
| Sidney Brown | M | 66 |
Georgetown University
| 4 years |
| Robert Steers | M | 70 |
Georgetown University
| 4 years |
| Cynthia Lewis Sweeting | F | - |
Georgetown University
| 4 years |
| Gregory Gerard Coleman | M | 69 |
Georgetown University
| 4 years |
| Peter Kenneth Pitsch | M | 72 |
Georgetown University
| 3 years |
| Michael Turits | M | - |
Georgetown University
| 4 years |
| Michael Patrick George | M | 73 |
Georgetown University
| 3 years |
| Bryan Ganz | M | 66 |
Georgetown University
| 4 years |
| Marilyn Alexander | F | 72 |
Georgetown University
| 3 years |
| John G. Quigley | M | - |
Georgetown University
| 4 years |
| Robert Sachs | M | 76 |
Georgetown University
| 3 years |
| Robert George Simses | M | 77 |
Georgetown University
| 3 years |
| Tom Meredith | M | 74 |
Georgetown University
| 2 years |
| Luke Sims | M | 74 |
Georgetown University
| 4 years |
| Catherine Britton | F | - |
Georgetown University
| 4 years |
| Ming Chung Tsai | M | 68 |
Georgetown University
| 3 years |
| Stephen T. Burdumy | M | 67 |
Georgetown University
| 4 years |
| Mark J. Macenka | M | - |
Georgetown University
| 4 years |
| Nancy S. Bryson | F | - |
Georgetown University
| 3 years |
| Henry Fernandez | M | 65 |
Georgetown University
| 4 years |
| Peter Thomas | M | 74 |
Georgetown University
| 3 years |
| James B. Dougherty | M | - |
Georgetown University
| 4 years |
| John B. Wade | M | - |
Georgetown University
| 3 years |
| Lane McVey | M | - |
Georgetown University
| 3 years |
| Paul Leming | M | - |
Georgetown University
| 2 years |
| Salvatore Massaro | M | - |
Georgetown University
| 4 years |
| Mark C. Gelnaw | M | - |
Georgetown University
| 4 years |
| Jordan M. Hadelman | M | - |
Georgetown University
| 4 years |
| Terran Andrews Miller | M | - |
Georgetown University
| 4 years |
| Eric L. Small | M | - |
Georgetown University
| 4 years |
| Edward L. Moorhouse | M | - |
Georgetown University
| 4 years |
| George J. Tenet | M | 71 |
Georgetown University
| 4 years |
| Jonathan B. Eddison | M | - |
Georgetown University
| 3 years |
| James M. Kessler | M | - |
Georgetown University
| 3 years |
| Nevin R. Harwood | M | - |
Georgetown University
| 1 years |
| Joseph J. Radecki | M | - |
Georgetown University
| 4 years |
| James J. Greco | M | 66 |
Georgetown University
| 4 years |
| Martin Buckland | M | 69 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | - |
| FEIRSTEIN ANDREA | F | - |
Georgetown University
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Elliott L. Fineman
- Personal Network
